The relationship between lipid accumulation products and non-alcoholic fatty liver disease among adults in the North of Iran: a cross-sectional study Authors: Catherine Behzad, Negin Atashi, Nasim Hafezi, Nima Motamed, Mansooreh Maadi, Elham Sobhrakhshankhah, Zainab Shateri, Farhad Zamani, Azam Doustmohammadian, Mehran Nouri Published: 2025 ABSTRACT BackgroundInsights into the relationship between adiposity and lipid metabolism are provided by the lipid accumulation product (LAP) index, which is particularly relevant in the context of non-alcoholic fatty liver disease (NAFLD). Therefore, the purpose of this research was to evaluate the relationship between the LAP index and NAFLD in the Iranian population.MethodsThe current cross-sectional study (n = 3,120) was conducted in the second stage of the Amol Cohort Study. NAFLD was confirmed to use ultrasound imaging. The values of the hepatic steatosis index (HSI) and LAP were obtained using the corresponding equations. Additionally, a multivariate logistic regression was performed to examine the relationship between LAP tertiles and both NAFLD and HSI.ResultsThe findings showed that there was a 1.8% increase in the odds of NAFLD and a 1.6% increase in the odds of HSI for each unit change in LAP score (P < 0.001 for both) in the adjusted model. Also, the analysis based on LAP tertiles found higher odds of NAFLD and HSI in the second tertile (NAFLD: odds ratio (OR) = 2.042, 95% confidence interval (CI): 1.578–2.642, P < 0.001 - HSI: OR = 1.765, 95% CI: 1.283–2.428, P < 0.001) and last tertile (NAFLD: OR = 3.607, 95% CI: 2.665–4.880, P < 0.001 - HSI: OR = 3.406, 95% CI: 2.282–5.083, P < 0.001) of LAP compared to the first tertile in the adjusted model.ConclusionsThe present research provides robust evidence that a higher LAP index is strongly associated with higher odds of NAFLD and hepatic steatosis.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12876-025-04353-5. Introduction Non-alcoholic fatty liver disease (NAFLD) refers to a range of liver conditions that include non-inflammatory isolated steatosis, which is characterized by the accumulation of triglycerides (TG) in liver cells. This is identified by the presence of lipid droplets in the cytoplasm of more than 5% of liver cells [1, 2]. Histologically, NAFLD encompasses a spectrum of conditions, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), and further progressing to cirrhosis, hepatic failure, advanced fibrosis, and potentially hepatocellular carcinoma [1, 3–6]. NAFLD is the most common chronic liver disease (CLD) globally, impacting approximately 25–33% of the worldwide population [7]. A global survey conducted in 2016 revealed that the incidence of NAFLD diagnosed through imaging is more than 25%, with rates of 23.71% in Europe, 27.37% in Asia, 24.13% in North America, 30.45% in South America, and 31.79% in the Middle East [8]. According to a 2024 meta-analysis, the prevalence of NAFLD among Iranian adults is approximately 35%, indicating a high and rising burden of disease at the national level [9]. Consequently, NAFLD is now widely acknowledged as the primary cause of CLD. Meanwhile, NASH is the second leading cause of cirrhosis among adults on the United States liver transplant waiting list. Projections indicate that NASH will likely surpass other causes and become the leading cause within the next ten years [10, 11]. Metabolic disorders play a crucial role in the onset and advancement of NAFLD [12]. Given that NAFLD is a chronic condition that develops over many years, regular screening and timely diagnosis in young individuals can help prevent serious complications, such as hepatocellular carcinoma and cirrhosis [13]. While liver biopsy remains the preferred method for diagnosing liver cirrhosis and NAFLD, its invasive nature renders it impractical for routine follow-up assessments [14]. Consequently, several studies have endeavored to discover effective and streamlined alternatives for epidemiological studies and comprehensive population health surveillance. These alternatives are aimed at enabling early detection of individuals at a heightened risk of developing NAFLD [15, 16]. Several biochemical and anthropometric indices, as well as combinations of these indices, have been developed to assess the risk of NAFLD in this context [17]. Amongst these markers, lipid-related and obesity indicators are considered to be the most effective in anticipating NAFLD and are frequently utilized in epidemiological research [17]. The lipid accumulation product (LAP) index is a novel biomarker for quantifying excessive lipid accumulation. It shows promise for predicting metabolic abnormalities [18]. The LAP index is easily calculated by readily available clinical measures, such as fasting TG and waist circumference (WC). This accessibility makes it a valuable tool for both epidemiological and clinical applications [18, 19]. Insights into the relationship between adiposity and lipid metabolism are provided by this index, which is particularly relevant in the context of NAFLD. The LAP reflects visceral adiposity and insulin resistance, both of which are key contributors to the pathogenesis of NAFLD [20, 21]. Furthermore, the LAP index is regarded as a feasible alternative for detecting NAFLD due to its non-invasive nature and low cost, in contrast to invasive and costly procedures like liver biopsy [22]. Previous studies have shown a significant association between LAP and NAFLD. Several studies, including the study by Dai et al. [13] and the study by Huang et al. study [23], have demonstrated that LAP may be a useful predictor of NAFLD. However, findings remain inconsistent across different ethnicities and age groups [24, 25], and no study has examined this association in the Iranian population, which is the focus of the present study. Therefore, the purpose of this research was to evaluate the relationship between the LAP index and NAFLD. The study aimed to develop efficient and affordable screening tools that can predict and assess the risk of NAFLD, ultimately improving early detection and intervention strategies for this common chronic liver condition. Materials and methods Study population The current cross-sectional study was conducted from the second stage of the Amol Cohort Study (AmolCS), a large cohort study in the northern region of Iran, especially in the city of Amol. The AmolCS consisted of individuals aged over 18 years who were monitored for diabetes mellitus (DM), metabolic syndrome (MetS), cardiovascular disease (CVD), and NAFLD. Sampling was done from 16 urban health centers and 25 rural health centers into 16 strata based on age and gender. Age groups were defined in ten-year intervals, from 18 to 89 years. In the current study, the people of each stratum were selected in proportion to the population size within that stratum. The selection process was done through a simple randomization method, as described in the study by Zamani et al. [26, 27]. Inclusion and exclusion criteria In this study, a total of 5,147 people over 18 years of age were examined. A total of 459 participants were excluded due to various reasons, including death (n = 77), migration (n = 25), or non-cooperation (n = 357) in the second phase. Furthermore, a total of 486 participants with a history of alcohol consumption, viral hepatitis, specific dietary restrictions, malignancy, thyroid disorders, autoimmune diseases, or missing/unreliable data on physical activity were excluded from the study. Additionally, 153 pregnant or lactating women were also excluded. A total of 929 participants were excluded from the study due to missing data on abdominal ultrasonography, incomplete dietary questionnaires, or implausible energy intake values based on Willett’s thresholds (i.e., < 500 or > 3,500 kcal/day for women, and < 800 or > 4,200 kcal/day for men). Finally, 3,120 subjects were eligible for analysis (Fig. 1). Fig. 1Flowchart of the study Flowchart of the study Anthropometric and clinical history assessments Trained personnel conducted anthropometric assessments following standardized protocols. Weight and height were measured using calibrated digital scales and stadiometers, with participants wearing light clothing and no shoes. Anthropometric variables, such as hip circumference (HC) and WC, were recorded. WC was measured at the midpoint between the lowest rib and the iliac crest using a non-elastic measuring tape. Also, the waist-to-height ratio (WHtR) was obtained by dividing WC (in meters) by height (in meters). In addition, waist-to-hip ratio (WHR) was determined by dividing WC (in meters) by HC (in meters). Moreover, the body mass index (BMI) was calculated by dividing an individual’s weight (in kilograms) by their height (in meters) squared. A checklist was completed by all participants to gather demographic, lifestyle, and clinical history information. The checklist included the following details: sex, age, residency area, smoking habits, alcohol consumption, and usage of glucose-lowering medications, lipid-lowering medications, and anti-hypertensive medications, as well as family history of chronic diseases. Using a validated International Physical Activity Questionnaire, physical activity level was assessed [2]. Laboratory assessments After a fasting period of 12 h, venous blood specimens were collected from each participant in the morning to assess their lipid profiles and fasting blood sugar (FBS) levels. Samples were processed within 2 h of collection, following standard protocols to ensure the stability of measurements. Following the protocol utilizing the BS200 Auto analyzer (Mindray, China), various tests were conducted including vitamin D, C-reactive protein (CRP), thyroxine (T4), triiodothyronine (T3), thyroid-stimulating hormone (TSH), gamma-glutamyl transferase (GGT), aspartate transaminase (AST), alanine transaminase (ALT), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), TG, FBS. The Friedewald equation was used to calculate serum low-density lipoprotein cholesterol (LDL-C). Nutritional assessments The participants’ typical diet was assessed using a semi-quantitative food frequency questionnaire (FFQ) comprised of 168 items, the validity of which has been previously established [28]. Trained interviewers gathered information about the participants’ diet. They recorded the quantity and frequency of each food consumed in the recent past. This information was then changed to grams per day using household measurements [29]. Finally, the data pertaining to each food item was extracted using Nutritionist IV software (First Databank, San Bruno, CA, USA). The software was designed specifically for Iranian foods [30]. Definition of NAFLD NAFLD was confirmed to use ultrasound imaging. The imaging showed increased echogenicity in the liver, as well as abnormal appearance of the diaphragm and hepatic arteries. These findings were observed in a patient who did not have viral or hereditary liver diseases, did not have drug-induced steatosis, and did not consume excessive alcohol. A linear array transducer with a frequency range of 3–5 MHz was used to capture intercostal, lateral, longitudinal, sagittal, and lateral views. The subjects were in a fasting state when a single experienced radiologist performed the diagnosis using ultrasound sonography. Also, the radiologist followed standardized protocols to ensure consistency in measurements. Definition of MetS Using the criteria established by the National Cholesterol Education Program Adult Treatment Panel III, MetS was identified [9]. The diagnosis criteria were the following: TG levels ≥ 150 mg/dL, or the use of medications for elevated TG levels.WC higher than 88 for women and 102 cm for men.FBS ≥ 100 mg/dL, or the use of medications for elevated blood glucose.The serum HDL-C level less than 50 mg/dL for women and less than 40 mg/dL for men.Systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg, or the use of medications for high blood pressure [10]. TG levels ≥ 150 mg/dL, or the use of medications for elevated TG levels. TG levels ≥ 150 mg/dL, or the use of medications for elevated TG levels. WC higher than 88 for women and 102 cm for men. WC higher than 88 for women and 102 cm for men. FBS ≥ 100 mg/dL, or the use of medications for elevated blood glucose. FBS ≥ 100 mg/dL, or the use of medications for elevated blood glucose. The serum HDL-C level less than 50 mg/dL for women and less than 40 mg/dL for men. The serum HDL-C level less than 50 mg/dL for women and less than 40 mg/dL for men. Systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg, or the use of medications for high blood pressure [10]. Systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg, or the use of medications for high blood pressure [10]. Calculation of indices Although abdominal ultrasonography is the standard imaging tool for NAFLD detection, its application may be limited in large-scale screening due to cost, operator dependence, and lack of accessibility in certain healthcare settings. The Hepatic Steatosis Index (HSI), derived from routine clinical parameters, offers a feasible alternative for non-invasive risk assessment. In this study, HSI was used to approximate NAFLD status in the absence of imaging data, and its association with LAP was analyzed to explore their complementary roles in identifying individuals at risk of hepatic steatosis. The values of the HSI, and LAP were obtained using the corresponding Eqs [6, 31]: LAP score: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$For\;men:LAP=\left(WC\left[cm\right]-65\right)\times TG\left[mmol/L\right]$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$For\;women:LAP=\left(WC\left[cm\right]-58\right)\times TG\left[mmol/L\right]$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\begin{aligned} HSI=&8\times\left(ALT/AST\;ratio\right)\\&+BMI\left(+2,\;if\;female;+2,\;if\;diabetes\;mellitus\right) \end{aligned}$$\end{document} Statistical analysis At first, the patient characteristics were grouped into tertiles based on the LAP. The descriptive statistics were reported as percentage for categorical variables and the mean ± standard deviation (SD) for continuous variables. Using the Kolmogorov-Smirnov test, the assessment of normality was conducted. A one-way analysis of variance (ANOVA) test was utilized to compare LAP tertiles across different variables, followed by Tukey’s test. A multivariate logistic regression was performed to examine the relationship between LAP tertiles and both NAFLD and HSI. Both crude and adjusted models were used to assess this association. Several covariates, such as energy intake, fiber intake, gender, residential area, current smoking status, alcohol consumption, family history of chronic diseases, physical activity level, MetS, and use of lipid-lowering, glucose-lowering, and anti-hypertensive medications were included in the adjusted model. Subgroup analyses were performed based on age, gender, and BMI, which are well-known effect modifiers in metabolic-related outcomes and have been commonly used in prior research on NAFLD and LAP. Other variables showing baseline differences were adjusted for multivariable models, but not used for stratification to maintain statistical robustness and avoid multiple comparison issues. We assessed the areas under the receiver operator characteristic (ROC) curves to evaluate LAP’s performance. The Youden index was employed to determine the optimal cutoff point, and sensitivity and specificity were determined at known cut-off points. SPSS (version 23) was used for data analysis. Also, R software (R version 4.4.1) was applied to depict all figures. A p-value of less than 0.05 was deemed to have statistical significance. Results Basic characteristics A total of 3,120 participants were included in the final analysis. Subsequently, these participants were categorized into tertiles according to their LAP scores. Table 1 summarizes the anthropometric, biochemical, and other baseline features of the study participants. Compared to the first tertile of LAP scores, the mean values of age, weight, WC, HC, BMI, WHR, WHtR, fiber intake, LAP, SBP, DBP, FBS, CRP, T3, GGT, AST, ALT, LDL-C, TC, TG, and hemoglobin A1c (HbA1c) levels were significantly higher in the second and last tertiles of LAP (P < 0.001 for all, except for T3). However, the mean values of height, HDL-C, AST to ALT ratio, and vitamin D in the first tertile were significantly higher (P < 0.001 for all, except for vitamin D).Table 1The baseline features of the study participants based on tertiles of lipid accumulation productsVariablesLAP IndexP-valueT1 (n=1,041)T2 (n=1,039)T3 (n=1,040)Socio-demographic featuresAge (year) 41.01 ± 15.80 a47.65 ± 13.63 b49.52 ± 12.38 c˂0.001Weight (kg)64.91 ± 10.72 a76.02 ± 11.33 b83.65 ± 13.92 c˂0.001Height (cm)165.56 ± 9.46 a163.77 ± 9.29 a163.82 ± 9.89 b˂0.001WC (cm)77.95 ± 7.65 a89.59 ± 7.06 b97.52 ± 8.85 c˂0.001HC (cm)95.29 ± 6.95 a102.07 ± 7.51 b105.99 ± 8.56 c˂0.001BMI (kg/m2)23.68 ± 3.43 a28.38 ± 3.99 b31.18 ± 4.63 c˂0.001WHR0.81 ± 0.07 a0.88 ± 0.07 b0.92 ± 0.07 c˂0.001WHtR0.47 ± 0.05 a0.54 ± 0.05 b0.59 ± 0.06 c˂0.001Energy intake (kcal/day)2476.1 ± 700.6 a2487.0 ± 683.3 a2466.7 ± 636.7 a0.791Fiber intake (g/day)38.10 ± 15.35 a40.57 ± 15.87 b40.78 ± 14.36 b˂0.001Gender, females, %38.144.846.4˂0.001Residual area, rural, %51.754.360.5˂0.001Current smoker, yes, %16.315.113.00.093Alcohol drinker, yes, %5.96.87.10.509Physical activity, % Low30.835.136.60.035 Moderate 36.036.234.14 High33.228.729.3Diseases historyFamily history of chronic diseases, yes, %12.116.517.50.001MetS, yes, %2.313.558.6˂0.001Lipid-lowering medications, yes, %5.58.712.5˂0.001Glucose-lowering medications, yes, %4.94.26.90.019Anti-hypertensive medications, yes, %10.211.015.7˂0.001Hepatic steatosis index31.87 ± 5.07 a38.00 ± 5.78 b41.88 ± 6.04 c˂0.001Hepatic steatosis index category No/mild fibrosis (HSI ≤ 36.0)80.739.414.2˂0.001 Advanced fibrosis (HSI ˃ 36.1)19.360.685.8Biochemical markersLAP13.05 ± 6.01 a33.21 ± 6.52 b78.72 ± 39.22 c˂0.001SBP (mmHg)106.66 ± 16.54 a114.70 ± 17.80 b121.06 ± 19.72 c˂0.001DBP (mmHg)66.94 ± 10.39 a71.70 ± 11.04 b75.23 ± 12.02 c˂0.001FBS (mg/dL)95.95 ± 23.76 a102.48 ± 26.91 b113.37 ± 40.75 c˂0.001HbA1c (%)4.36 ± 0.86 a4.54 ± 0.83 b4.66 ± 0.88 c˂0.001TG (mg/dL)77.91 ± 29.24 a112.14 ± 33.44 b202.78 ± 100.73 c˂0.001TC (mg/dL)166.01 ± 34.39 a179.60 ± 35.54 b194.29 ± 43.23 c˂0.001LDL-C (mg/dL)92.13 ± 24.61 a100.82 ± 25.53 b104.05 ± 26.43 c˂0.001HDL-C (mg/dL)46.19 ± 11.15 a44.11 ± 11.52 b41.39 ± 11.07 c˂0.001ALT (mg/dL)19.53 ± 14.22 a24.19 ± 18.78 b28.92 ± 20.72 c˂0.001AST (mg/dL)20.95 ± 12.23 a21.56 ± 9.78 a22.79 ± 9.39 c˂0.001AST to ALT ratio1.23 ± 0.47 a1.06 ± 0.42 b0.93 ± 0.36 c˂0.001GGT (mg/dL)21.18 ± 14.87 a26.75 ± 17.95 b31.57 ± 19.39 c˂0.001T3 (ng/dL)1.98 ± 1.04 a2.02 ± 1.03 a2.21 ± 1.31 c0.002T4 (ng/dL)9.45 ± 2.51 a9.46 ± 2.69 a9.43 ± 2.51 a0.965CRP (mg/dL)1.61 ± 2.00 a2.27 ± 2.24 b2.62 ± 2.41 c˂0.001Vitamin D (ng/dL)1.51 ± 1.37 a1.47 ± 1.43 b1.31 ± 1.22 b0.001Using One-way ANOVA test for parametric continuous variables and values are mean ± SDUsing chi-square test for categorical variables and values are frequency (percentage)Significant values are shown in boldOne-way ANOVA test followed by Tukey’s test was usedWelch One-way ANOVA test followed by Tukey’s test was usedDifferent superscript letters (a, b, c) across a row indicate statistically significant differences at p < 0.05 according to Tukey's post-hoc test. Means sharing the same letter (aa, bb or cc) do not differ significantlyAbbreviations: WC waist circumference, HC hip circumference, BMI body mass index, WHR waist to hip ratio, WHtR waist to height ratio, HSI hepatic steatosis index, LAP lipid accumulation products, SBP systolic blood pressure, DBP diastolic blood pressure, FBS fasting blood sugar, HbA1c hemoglobin A1c, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, ALT alanine transaminase, AST aspartate transaminase, GGT gamma-glutamyl transferase, TSH thyroid-stimulating hormone, CRP c-reactive protein, T4 thyroxine T3 triiodothyronine Table 1The baseline features of the study participants based on tertiles of lipid accumulation productsVariablesLAP IndexP-valueT1 (n=1,041)T2 (n=1,039)T3 (n=1,040)Socio-demographic featuresAge (year) 41.01 ± 15.80 a47.65 ± 13.63 b49.52 ± 12.38 c˂0.001Weight (kg)64.91 ± 10.72 a76.02 ± 11.33 b83.65 ± 13.92 c˂0.001Height (cm)165.56 ± 9.46 a163.77 ± 9.29 a163.82 ± 9.89 b˂0.001WC (cm)77.95 ± 7.65 a89.59 ± 7.06 b97.52 ± 8.85 c˂0.001HC (cm)95.29 ± 6.95 a102.07 ± 7.51 b105.99 ± 8.56 c˂0.001BMI (kg/m2)23.68 ± 3.43 a28.38 ± 3.99 b31.18 ± 4.63 c˂0.001WHR0.81 ± 0.07 a0.88 ± 0.07 b0.92 ± 0.07 c˂0.001WHtR0.47 ± 0.05 a0.54 ± 0.05 b0.59 ± 0.06 c˂0.001Energy intake (kcal/day)2476.1 ± 700.6 a2487.0 ± 683.3 a2466.7 ± 636.7 a0.791Fiber intake (g/day)38.10 ± 15.35 a40.57 ± 15.87 b40.78 ± 14.36 b˂0.001Gender, females, %38.144.846.4˂0.001Residual area, rural, %51.754.360.5˂0.001Current smoker, yes, %16.315.113.00.093Alcohol drinker, yes, %5.96.87.10.509Physical activity, % Low30.835.136.60.035 Moderate 36.036.234.14 High33.228.729.3Diseases historyFamily history of chronic diseases, yes, %12.116.517.50.001MetS, yes, %2.313.558.6˂0.001Lipid-lowering medications, yes, %5.58.712.5˂0.001Glucose-lowering medications, yes, %4.94.26.90.019Anti-hypertensive medications, yes, %10.211.015.7˂0.001Hepatic steatosis index31.87 ± 5.07 a38.00 ± 5.78 b41.88 ± 6.04 c˂0.001Hepatic steatosis index category No/mild fibrosis (HSI ≤ 36.0)80.739.414.2˂0.001 Advanced fibrosis (HSI ˃ 36.1)19.360.685.8Biochemical markersLAP13.05 ± 6.01 a33.21 ± 6.52 b78.72 ± 39.22 c˂0.001SBP (mmHg)106.66 ± 16.54 a114.70 ± 17.80 b121.06 ± 19.72 c˂0.001DBP (mmHg)66.94 ± 10.39 a71.70 ± 11.04 b75.23 ± 12.02 c˂0.001FBS (mg/dL)95.95 ± 23.76 a102.48 ± 26.91 b113.37 ± 40.75 c˂0.001HbA1c (%)4.36 ± 0.86 a4.54 ± 0.83 b4.66 ± 0.88 c˂0.001TG (mg/dL)77.91 ± 29.24 a112.14 ± 33.44 b202.78 ± 100.73 c˂0.001TC (mg/dL)166.01 ± 34.39 a179.60 ± 35.54 b194.29 ± 43.23 c˂0.001LDL-C (mg/dL)92.13 ± 24.61 a100.82 ± 25.53 b104.05 ± 26.43 c˂0.001HDL-C (mg/dL)46.19 ± 11.15 a44.11 ± 11.52 b41.39 ± 11.07 c˂0.001ALT (mg/dL)19.53 ± 14.22 a24.19 ± 18.78 b28.92 ± 20.72 c˂0.001AST (mg/dL)20.95 ± 12.23 a21.56 ± 9.78 a22.79 ± 9.39 c˂0.001AST to ALT ratio1.23 ± 0.47 a1.06 ± 0.42 b0.93 ± 0.36 c˂0.001GGT (mg/dL)21.18 ± 14.87 a26.75 ± 17.95 b31.57 ± 19.39 c˂0.001T3 (ng/dL)1.98 ± 1.04 a2.02 ± 1.03 a2.21 ± 1.31 c0.002T4 (ng/dL)9.45 ± 2.51 a9.46 ± 2.69 a9.43 ± 2.51 a0.965CRP (mg/dL)1.61 ± 2.00 a2.27 ± 2.24 b2.62 ± 2.41 c˂0.001Vitamin D (ng/dL)1.51 ± 1.37 a1.47 ± 1.43 b1.31 ± 1.22 b0.001Using One-way ANOVA test for parametric continuous variables and values are mean ± SDUsing chi-square test for categorical variables and values are frequency (percentage)Significant values are shown in boldOne-way ANOVA test followed by Tukey’s test was usedWelch One-way ANOVA test followed by Tukey’s test was usedDifferent superscript letters (a, b, c) across a row indicate statistically significant differences at p < 0.05 according to Tukey's post-hoc test. Means sharing the same letter (aa, bb or cc) do not differ significantlyAbbreviations: WC waist circumference, HC hip circumference, BMI body mass index, WHR waist to hip ratio, WHtR waist to height ratio, HSI hepatic steatosis index, LAP lipid accumulation products, SBP systolic blood pressure, DBP diastolic blood pressure, FBS fasting blood sugar, HbA1c hemoglobin A1c, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, ALT alanine transaminase, AST aspartate transaminase, GGT gamma-glutamyl transferase, TSH thyroid-stimulating hormone, CRP c-reactive protein, T4 thyroxine T3 triiodothyronine The baseline features of the study participants based on tertiles of lipid accumulation products Using One-way ANOVA test for parametric continuous variables and values are mean ± SD Using chi-square test for categorical variables and values are frequency (percentage) Significant values are shown in bold One-way ANOVA test followed by Tukey’s test was used Welch One-way ANOVA test followed by Tukey’s test was used Different superscript letters (a, b, c) across a row indicate statistically significant differences at p < 0.05 according to Tukey's post-hoc test. Means sharing the same letter (aa, bb or cc) do not differ significantly Abbreviations: WC waist circumference, HC hip circumference, BMI body mass index, WHR waist to hip ratio, WHtR waist to height ratio, HSI hepatic steatosis index, LAP lipid accumulation products, SBP systolic blood pressure, DBP diastolic blood pressure, FBS fasting blood sugar, HbA1c hemoglobin A1c, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, ALT alanine transaminase, AST aspartate transaminase, GGT gamma-glutamyl transferase, TSH thyroid-stimulating hormone, CRP c-reactive protein, T4 thyroxine T3 triiodothyronine Meanwhile, compared to participants with a low LAP score, participants in the groups with higher LAP scores had a higher proportion of females and more individuals living in rural areas (P < 0.001 for both). Additionally, in the last tertile of LAP, anti-hypertensive medication use (P < 0.001), glucose-lowering medication use (P = 0.019), lipid-lowering medication use (P < 0.001), MetS (P < 0.001), and the percentage of family history of chronic diseases (P = 0.001) were significantly higher compared to the first tertile. NAFLD prevalence Figure 2 shows the prevalence rates of NAFLD in the three LAP groups, both for the total population and based on gender. The prevalence rates of NAFLD were significantly higher in the total population, as well as in both females and males (P < 0.001 for all).Fig. 2The prevalence of NAFLD according to the tertiles of LAP in total population and based on gender. Abbreviations: NAFLD, non-alcoholic fatty liver disease; LAP, lipid accumulation products. Using chi-square test for categorical variables and values are frequency (percentage). * The p-value was less than 0.001 for the prevalence of NAFLD according to the tertiles of LAP in the total population, males, and females The prevalence of NAFLD according to the tertiles of LAP in total population and based on gender. Abbreviations: NAFLD, non-alcoholic fatty liver disease; LAP, lipid accumulation products. Using chi-square test for categorical variables and values are frequency (percentage). * The p-value was less than 0.001 for the prevalence of NAFLD according to the tertiles of LAP in the total population, males, and females Relationship between NAFLD and HSI with LAP The relationship between NAFLD odds and HSI with LAP, based on the total score and tertiles of LAP, is reported in Table 2. In the crude model, there was a 3.9% increase in the odds of NAFLD and a 5.7% increase in the odds of HSI for each unit increase in LAP score (P < 0.001 for both). There was a 1.8% increase in the odds of NAFLD and a 1.6% increase in the odds of HSI for each unit change in LAP score (P < 0.001 for both) in the adjusted model.Table 2The association between the odds of non-alcoholic fatty liver disease and hepatic steatosis index with lipid accumulation productsVariablesOR (95% CI)P-valueT1T2 P-valueT3P-valueOR (95% CI)OR (95% CI)Non-alcoholic fatty liver diseaseCrude modelAdjusted model1.039 (1.036-1.043)1.018 (1.013-1.022)˂0.001˂0.001Ref.Ref.4.376 (3.555-5.387)2.042 (1.578-2.642)˂0.001˂0.00114.136 (11.391-17.541)3.607 (2.665-4.880)˂0.001˂0.001Hepatic steatosis indexCrude modelAdjusted model1.057 (1.052-1.061)1.016 (1.009-1.022)˂0.001˂0.001Ref.Ref.6.417 (5.264-7.822)1.765 (1.283-2.428)˂0.001˂0.00125.188 (19.967-31.773)3.406 (2.282-5.083)˂0.001˂0.001Significant values are shown in boldThese values are odds ratios (95% CIs)Obtained from logistic regression by enter methodAbbreviations: OR odds ratio, CI confidence interval, Ref reference, T tertileAdjusted model: adjusted for age (years), BMI (kg/m2), energy intake (kcal/day), fiber intake (g/day), gender (females/males), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes) Table 2The association between the odds of non-alcoholic fatty liver disease and hepatic steatosis index with lipid accumulation productsVariablesOR (95% CI)P-valueT1T2 P-valueT3P-valueOR (95% CI)OR (95% CI)Non-alcoholic fatty liver diseaseCrude modelAdjusted model1.039 (1.036-1.043)1.018 (1.013-1.022)˂0.001˂0.001Ref.Ref.4.376 (3.555-5.387)2.042 (1.578-2.642)˂0.001˂0.00114.136 (11.391-17.541)3.607 (2.665-4.880)˂0.001˂0.001Hepatic steatosis indexCrude modelAdjusted model1.057 (1.052-1.061)1.016 (1.009-1.022)˂0.001˂0.001Ref.Ref.6.417 (5.264-7.822)1.765 (1.283-2.428)˂0.001˂0.00125.188 (19.967-31.773)3.406 (2.282-5.083)˂0.001˂0.001Significant values are shown in boldThese values are odds ratios (95% CIs)Obtained from logistic regression by enter methodAbbreviations: OR odds ratio, CI confidence interval, Ref reference, T tertileAdjusted model: adjusted for age (years), BMI (kg/m2), energy intake (kcal/day), fiber intake (g/day), gender (females/males), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes) The association between the odds of non-alcoholic fatty liver disease and hepatic steatosis index with lipid accumulation products Crude model Adjusted model 1.039 (1.036-1.043) 1.018 (1.013-1.022) ˂0.001 ˂0.001 Ref. Ref. 4.376 (3.555-5.387) 2.042 (1.578-2.642) ˂0.001 ˂0.001 14.136 (11.391-17.541) 3.607 (2.665-4.880) ˂0.001 ˂0.001 Crude model Adjusted model 1.057 (1.052-1.061) 1.016 (1.009-1.022) ˂0.001 ˂0.001 Ref. Ref. 6.417 (5.264-7.822) 1.765 (1.283-2.428) ˂0.001 ˂0.001 25.188 (19.967-31.773) 3.406 (2.282-5.083) ˂0.001 ˂0.001 Significant values are shown in bold These values are odds ratios (95% CIs) Obtained from logistic regression by enter method Abbreviations: OR odds ratio, CI confidence interval, Ref reference, T tertile Adjusted model: adjusted for age (years), BMI (kg/m2), energy intake (kcal/day), fiber intake (g/day), gender (females/males), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes) Also, the analysis based on LAP tertiles found higher odds of NAFLD and HSI in the second tertile (NAFLD: OR = 4.376, 95% CI: 3.555–5.387, P < 0.001 - HSI: OR = 6.417, 95% CI: 5.264–7.822, P < 0.001) and last tertile (NAFLD: OR = 14.136, 95% CI: 11.391–17.541, P < 0.001 - HSI: OR = 25.188, 95% CI: 19.967–31.773, P < 0.001) of LAP compared to the first tertile in the crude model. After adjusting for energy intake (kcal/day), BMI (kg/m2), age (years), fiber intake (g/day), gender (females/males), family history of chronic diseases (no/yes), physical activity level (low/moderate/high), residential area (rural/urban), current smoking status (no/yes), alcohol consumption (no/yes), MetS (no/yes), and use of glucose-lowering (no/yes), lipid-lowering (no/yes), and anti-hypertensive medications (no/yes), all associations in the second tertile (NAFLD: OR = 2.042, 95% CI: 1.578–2.642, P ˂ 0.001 - HSI: OR = 1.765, 95% CI: 1.283–2.428, P ˂ 0.001) and last tertiles (NAFLD: OR = 3.607, 95% CI: 2.665–4.880, P ˂ 0.001 - HSI: OR = 3.406, 95% CI: 2.282–5.083, P ˂ 0.001) of LAP remained significant. Stratified relationship between NAFLD and HSI with LAP The relationship between the chance of NAFLD and HSI with LAP, stratified based on the total score of LAP, is presented in Table 3.Table 3The AUC for LAP for the diagnosis of non-alcoholic fatty liver disease in the total population and by genderVariablesNo. of participantsCrude modelOR (95% CI)P-valueAdjusted modelOR (95% CI)P-valueNon-alcoholic fatty liver diseaseGender Males17751.043 (1.038–1.048)˂0.0011.017 (1.011–1.024)˂0.001 a Females13451.033 (1.031–1.041)˂0.0011.014 (1.008–1.021)˂0.001Age (years) Less than 305531.055 (1.043–1.067)˂0.0011.017 (1.003–1.031)0.014 b 30–459651.036 (1.030–1.043)˂0.0011.016 (1.009–1.024)˂0.001 46–6010581.032 (1.026–1.038)˂0.0011.015 (1.008–1.023)˂0.001 More than 605441.039 (1.031–1.048)˂0.0011.017 (1.006–1.028)0.003BMI (kg/m2) Less than 25 955 1.035 (1.024–1.046) ˂0.001 1.045 (1.030–1.060) ˂0.001 c 25–3012441.022 (1.017–1.027)˂0.0011.016 (1.010–1.022)˂0.001 More than 309211.025 (1.019–1.031)˂0.0011.017 (1.010–1.025)˂0.001Hepatic steatosis indexGender Males17751.057 (1.051–1.063)˂0.0011.020 (1.012–1.029)˂0.001 a Females13451.061 (1.052–1.069)˂0.0011.008 (0.998–1.018)0.122Age (years) Less than 305531.097 (1.079–1.116)˂0.0011.037 (1.013–1.062)0.002 b 30–459651.050 (1.042–1.059)˂0.0011.014 (1.003–1.026)0.014 46–6010581.057 (1.048–1.065)˂0.0011.010 (0.999–1.021)0.075 More than 605441.054 (1.044–1.064)˂0.0011.013 (0.997–1.030)0.108BMI (kg/m2) Less than 259551.036 (1.023–1.049)˂0.0011.056 (1.036–1.077)˂0.001 c 25–3012441.017 (1.012–1.023)˂0.0011.020 (1.013–1.027)˂0.001 More than 309211.007 (0.988–1.027)0.4701.022 (0.994–1.051)0.124Significant values are shown in boldThese values are odds ratios (95% CIs)Obtained from logistic regression by enter methodAbbreviations: OR odds ratio, CI confidence interval, BMI body mass indexAdjusted model a: adjusted for age (years), BMI (kg/m2), energy intake (kcal/day), fiber intake (g/day), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes)Adjusted model b: adjusted for BMI (kg/m2), energy intake (kcal/day), fiber intake (g/day), gender (females/males), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes)Adjusted model c: adjusted for age (year), energy intake (kcal/day), fiber intake (g/day), gender (females/males), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes) Table 3The AUC for LAP for the diagnosis of non-alcoholic fatty liver disease in the total population and by genderVariablesNo. of participantsCrude modelOR (95% CI)P-valueAdjusted modelOR (95% CI)P-valueNon-alcoholic fatty liver diseaseGender Males17751.043 (1.038–1.048)˂0.0011.017 (1.011–1.024)˂0.001 a Females13451.033 (1.031–1.041)˂0.0011.014 (1.008–1.021)˂0.001Age (years) Less than 305531.055 (1.043–1.067)˂0.0011.017 (1.003–1.031)0.014 b 30–459651.036 (1.030–1.043)˂0.0011.016 (1.009–1.024)˂0.001 46–6010581.032 (1.026–1.038)˂0.0011.015 (1.008–1.023)˂0.001 More than 605441.039 (1.031–1.048)˂0.0011.017 (1.006–1.028)0.003BMI (kg/m2) Less than 25 955 1.035 (1.024–1.046) ˂0.001 1.045 (1.030–1.060) ˂0.001 c 25–3012441.022 (1.017–1.027)˂0.0011.016 (1.010–1.022)˂0.001 More than 309211.025 (1.019–1.031)˂0.0011.017 (1.010–1.025)˂0.001Hepatic steatosis indexGender Males17751.057 (1.051–1.063)˂0.0011.020 (1.012–1.029)˂0.001 a Females13451.061 (1.052–1.069)˂0.0011.008 (0.998–1.018)0.122Age (years) Less than 305531.097 (1.079–1.116)˂0.0011.037 (1.013–1.062)0.002 b 30–459651.050 (1.042–1.059)˂0.0011.014 (1.003–1.026)0.014 46–6010581.057 (1.048–1.065)˂0.0011.010 (0.999–1.021)0.075 More than 605441.054 (1.044–1.064)˂0.0011.013 (0.997–1.030)0.108BMI (kg/m2) Less than 259551.036 (1.023–1.049)˂0.0011.056 (1.036–1.077)˂0.001 c 25–3012441.017 (1.012–1.023)˂0.0011.020 (1.013–1.027)˂0.001 More than 309211.007 (0.988–1.027)0.4701.022 (0.994–1.051)0.124Significant values are shown in boldThese values are odds ratios (95% CIs)Obtained from logistic regression by enter methodAbbreviations: OR odds ratio, CI confidence interval, BMI body mass indexAdjusted model a: adjusted for age (years), BMI (kg/m2), energy intake (kcal/day), fiber intake (g/day), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes)Adjusted model b: adjusted for BMI (kg/m2), energy intake (kcal/day), fiber intake (g/day), gender (females/males), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes)Adjusted model c: adjusted for age (year), energy intake (kcal/day), fiber intake (g/day), gender (females/males), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes) The AUC for LAP for the diagnosis of non-alcoholic fatty liver disease in the total population and by gender Significant values are shown in bold These values are odds ratios (95% CIs) Obtained from logistic regression by enter method Abbreviations: OR odds ratio, CI confidence interval, BMI body mass index Adjusted model a: adjusted for age (years), BMI (kg/m2), energy intake (kcal/day), fiber intake (g/day), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes) Adjusted model b: adjusted for BMI (kg/m2), energy intake (kcal/day), fiber intake (g/day), gender (females/males), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes) Adjusted model c: adjusted for age (year), energy intake (kcal/day), fiber intake (g/day), gender (females/males), residual area (rural/urban), current smoker (no/yes), alcohol drinker (no/yes), physical activity (low/moderate/high), family history of chronic diseases (no/yes), MetS (no/yes), and lipid-lowering (no/yes), glucose-lowering (no/yes), and anti-hypertensive medications (no/yes) In stratified analyses, the association between LAP and NAFLD remained statistically significant across all subgroups in both models. For gender subgroups, the adjusted OR for NAFLD per unit increase in LAP was 1.017 (95% CI: 1.011–1.024, p < 0.001) in males and 1.014 (95% CI: 1.008–1.021, p < 0.001) in females. With respect to age categories, adjusted ORs were as follows: <30 years: 1.017 (95% CI: 1.003–1.031, p = 0.014), 30–45 years: 1.016 (95% CI: 1.009–1.024, p < 0.001), 46–60 years: 1.015 (95% CI: 1.008–1.023, p < 0.001), and > 60 years: 1.017 (95% CI: 1.006–1.028, p = 0.003). Regarding BMI groups, the association remained significant in all strata: BMI < 25: 1.045 (95% CI: 1.030–1.060, p < 0.001), BMI 25–30: 1.016 (95% CI: 1.010–1.022, p < 0.001), and BMI > 30: 1.017 (95% CI: 1.010–1.025, p < 0.001). For the association between LAP and HSI, adjusted ORs were also significant in most strata. In males, the OR was 1.020 (95% CI: 1.012–1.029, p < 0.001), while in females, the association was not statistically significant (OR = 1.008; 95% CI: 0.998–1.018, p = 0.122). Across age categories, adjusted ORs were: <30 years: 1.037 (95% CI: 1.013–1.062, p = 0.002), 30–45 years: 1.014 (95% CI: 1.003–1.026, p = 0.014), 46–60 years: 1.010 (95% CI: 0.999–1.021, p = 0.075), and > 60 years: 1.013 (95% CI: 0.997–1.030, p = 0.108). When stratified by BMI: BMI < 25: 1.056 (95% CI: 1.036–1.077, p < 0.001), BMI 25–30: 1.020 (95% CI: 1.013–1.027, p < 0.001), and BMI > 30: 1.022 (95% CI: 0.994–1.051, p = 0.124). Determination of the optimal cut-off value for NAFLD Table 4 and Fig. 3 present the ROC analysis results of LAP for identifying NAFLD in the entire population, as well as separately for males and females. The results indicate that the AUC of LAP for detecting NAFLD in the total population was 0.791. For males, the AUC was 0.793, while for females, it was 0.789. The cut-off value for both the total population and males was 35.396, while for female participants it was 33.533. These LAP cut-off values represent optimal thresholds for identifying individuals at increased risk for NAFLD. In clinical practice, values above these cut-offs may warrant further diagnostic work-up or preventive strategies, highlighting their potential utility in early risk stratification.Table 4The AUC for LAP for the diagnosis of non-alcoholic fatty liver disease in the total population and by genderVariablesAUC 95% CI low 95% CI up Cutoff value SensitivitySpecificityTotal populationLAP0.7910.7750.80635.3960.7110.739MalesLAP0.7930.7720.81335.3960.6870.761FemalesLAP0.7890.7650.81333.5330.7790.678Obtained from receiver operating characteristic (ROC) analysisAbbreviations: AUC area under the curve, CI confidence interval, LAP lipid accumulation products Fig. 3The AUC for (A) LAP in the total population, (B) LAP in males, and (C) LAP in females. Abbreviations: AUC, area under the curve; LAP, lipid accumulation products. Obtained from receiver operating characteristic (ROC) analysis Table 4The AUC for LAP for the diagnosis of non-alcoholic fatty liver disease in the total population and by genderVariablesAUC 95% CI low 95% CI up Cutoff value SensitivitySpecificityTotal populationLAP0.7910.7750.80635.3960.7110.739MalesLAP0.7930.7720.81335.3960.6870.761FemalesLAP0.7890.7650.81333.5330.7790.678Obtained from receiver operating characteristic (ROC) analysisAbbreviations: AUC area under the curve, CI confidence interval, LAP lipid accumulation products The AUC for LAP for the diagnosis of non-alcoholic fatty liver disease in the total population and by gender Obtained from receiver operating characteristic (ROC) analysis Abbreviations: AUC area under the curve, CI confidence interval, LAP lipid accumulation products The AUC for (A) LAP in the total population, (B) LAP in males, and (C) LAP in females. Abbreviations: AUC, area under the curve; LAP, lipid accumulation products. Obtained from receiver operating characteristic (ROC) analysis Discussion The findings from the current study indicated a significant positive relationship between LAP and the odds of NAFLD, as well as the HSI. LAP was positively associated with NAFLD across different genders, ages, and BMI categories. However, LAP showed a significant positive relationship with the HSI specifically in males, individuals under 45 years old, and those with a BMI under 30. No association was observed between LAP and HSI in females, individuals over 45 years of age, or obese participants. NAFLD, which is the most common chronic liver disease, affects approximately 25% of the adult population worldwide [8]. There is a growing number of studies that aim to identify practical and reliable predictors for NAFLD, which is crucial in clinical settings. NAFLD is strongly associated with type 2 DM (T2DM), obesity, and MetS. Consequently, it is recommended to screen individuals with these conditions for NAFLD [32, 33]. In recent years, numerous studies have confirmed a strong link between LAP index and cardiometabolic risk factors [34, 35]. For example, Taverna et al. conducted a cross-sectional study that demonstrated the LAP index’s exceptional accuracy in diagnosing MetS, which is also closely linked to NAFLD [36, 37]. LAP index has been proven to have a positive correlation with the risk of NAFLD [23, 38], and serves as a reliable indicator for hepatic steatosis [39, 40]. These findings align with the outcomes of our cross-sectional study. Also, LAP has demonstrated considerable utility not only in identifying NAFLD but also as a marker for metabolic dysfunction across various populations and conditions. For instance, in women with polycystic ovary syndrome (PCOS), LAP has been correlated with MetS in normal-weight and overweight women and cardiovascular risk, offering a practical tool for early risk stratification [41, 42]. Motamed et al. discovered that WC is a highly effective diagnostic tool for identifying NAFLD, with an AUC of 0.85 and a 95% CI of 0.84–0.86 [43]. An increase in WC is indicative of the accumulation of excessive visceral fat. This can lead to the synthesis of cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6), which trigger inflammation and the infiltration of macrophages. As a result, liver inflammation and fibrosis are exacerbated [44]. Furthermore, elevated levels of TG can promote the transportation of free fatty acids (FFA) to the liver, thus contributing to the development of NAFLD [45]. Furthermore, studies have demonstrated that omega-3 fatty acids can effectively decrease liver steatosis by reducing TG levels. This provides additional evidence supporting the notion that elevated TG plays a significant role in the development of NAFLD [46]. Consequently, LAP, calculated from TG and WC, is closely associated with hepatic pathological changes and NAFLD. Also, studies have found a significant link between the severity of hepatic steatosis and the levels of ALT and AST in children who are overweight or obese [47] with elevated liver enzymes often indicating early NAFLD diagnosis [48]. According to Ulasoglu et al., around 21% of patients with biopsy-confirmed NAFLD were found to have normal levels of liver enzymes [49, 50], reinforcing the notion that aminotransferase levels alone are not definitive indicators of liver damage [50–52]. Moreover, conditions such as Wilson’s disease, autoimmune hepatitis, alpha-1 antitrypsin deficiency, hereditary hemochromatosis, hepatitis C, hepatitis B, and drug-induced liver injury can also cause elevated transaminase levels [53]. Contrary to our findings, Liu et al. reported a more pronounced correlation between LAP and NAFLD in females as opposed to males [38]. This difference could be attributed to the way estrogen affects vascular inflammation, lipid metabolism, plaque progression, and cell growth in premenopausal women. Menopause causes biological and physiological changes, including glucose intolerance, dyslipidemia, and the accumulation of visceral fat. These changes are closely linked to NAFLD, CVD, and increased insulin resistance (IR) [54]. Sex differences in the utility of LAP as a marker for metabolic risk have been reported [25], with menopausal status playing a critical role in modulating these differences [54]. Menopause is associated with hormonal changes that lead to increased central adiposity and altered lipid metabolism, factors that can influence LAP values and their predictive power [55, 56]. Studies in diverse populations have shown that postmenopausal women have greater central adiposity, dyslipidemia, increased inflammation, and a higher prevalence of MetS than premenopausal women [57–59]. This suggests that LAP performance may differ by menopausal status, highlighting that stratification by menopause could improve LAP’s precision and clinical utility in risk assessment. The stronger association between LAP and prevalent NAFLD observed in younger and lower-BMI individuals may be explained by several factors. Younger individuals may exhibit greater hepatic sensitivity to lipid accumulation or may not yet present other competing metabolic comorbidities, making the impact of LAP on NAFLD more apparent. Similarly, in lower-BMI populations, LAP might better capture subtle visceral adiposity and metabolic disturbances that are not reflected by BMI alone, highlighting its role as a sensitive indicator of hepatic fat deposition even among non-obese individuals. These findings suggest that LAP could be particularly useful for early risk stratification in populations traditionally considered at lower risk. One of the main strengths of this study is its large sample size, comprising individuals from a northern Iranian population who underwent liver ultrasound, which allowed us to evaluate the diagnostic performance of LAP for ultrasound-confirmed NAFLD. In our cohort, the optimal LAP cutoff for identifying NAFLD was 0.791. Comparable studies in other populations have reported varying thresholds and diagnostic performance. For instance, in a Chinese cohort, LAP demonstrated sex-specific AUC values of 0.843 for men and 0.887 for women [60]. In a US (NHANES) cohort, an AUC of 0.813 was reported for LAP in predicting as metabolic dysfunction-associated steatosis liver disease (MASLD) [61]. Additionally, a Turkish cohort study reported a LAP cutoff of 42.7 for the prediction of NAFLD [62]. Additionally, we adjusted for potential confounders in regression models. However, we should acknowledge some limitations. The cross-sectional design of the study hinders our capacity to establish causality in the observed associations. The study only evaluates the association between LAP and NAFLD, and causal relationships could not be determined, necessitating prospective studies for confirmation. Furthermore, the results should be cautiously generalized to other regions, as the research was conducted in northern Iran. Although our study was originally conducted using the NAFLD framework, it is important to note that this condition has recently been redefined as MASLD. While we did not collect all criteria required for a formal MASLD diagnosis, such as insulin resistance markers or hs-CRP, most of our participants with hepatic steatosis also exhibited metabolic risk factors, including elevated BMI, triglycerides, and fasting glucose. Thus, our population largely aligns with the conceptual basis of MASLD, and our findings remain relevant in the context of this updated classification. Conclusions The present research provides robust evidence that a higher LAP index significantly increases the risk of NAFLD and hepatic steatosis. The LAP measurement is simple, non-invasive, and cost-effective, making it suitable for large-scale application in hepatic steatosis and early-stage NAFLD screening. Consequently, these findings could facilitate more rapid screening and diagnosis of NAFLD in clinical practice. Implementing LAP as a standard screening tool could improve early detection rates, allowing for timely intervention and management, potentially reducing the progression to more severe liver diseases. Furthermore, this approach could lead to better resource allocation in healthcare settings, emphasizing preventive measures and reducing the need for more invasive diagnostic procedures. Therefore, the LAP index stands out as a promising marker to improve clinical outcomes in patients at risk for NAFLD, ultimately contributing to better overall public health outcomes. Supplementary Information Supplementary Material 1. Supplementary Material 1.